iBio Inc., a biotechnology company, has filed an amendment to a registration statement with the U.S. Securities and Exchange Commission (SEC) on July 25, 2024, for the potential sale of up to $150,000,000 in various securities. The securities may include common stock, preferred stock, debt securities, warrants, or units. The company has entered into an At Market Issuance Sales Agreement with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC to offer up to $7,350,000 of common stock. The sales may be made through 'at the market' offerings, and the proceeds are intended for working capital and general corporate purposes, which may include acquisitions, licensing, investments, or repurchasing securities. iBio Inc. has not specified the number of shares or the price range for the offering. The company's common stock is listed on the NYSE American under the symbol 'IBIO'.

iBio Inc., a biotechnology company, has filed an amendment to a registration statement with the U.S. Securities and Exchange Commission (SEC) on July 25, 2024, for the potential sale of up to $150,000,000 in various securities. The securities may include common stock, preferred stock, debt securities, warrants, or units. The company has entered into an At Market Issuance Sales Agreement with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC to offer up to $7,350,000 of common stock. The sales may be made through 'at the market' offerings, and the proceeds are intended for working capital and general corporate purposes, which may include acquisitions, licensing, investments, or repurchasing securities. iBio Inc. has not specified the number of shares or the price range for the offering. The company's common stock is listed on the NYSE American under the symbol 'IBIO'.